A carregar...
The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia
Antibody–drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an ex...
Na minha lista:
| Publicado no: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4556970/ https://ncbi.nlm.nih.gov/pubmed/26425338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620715596715 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|